MedTrace Logo

Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease

NCT00427284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2011-12-23

No results posted yet for this study

Summary

The aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with Eplerenone as potential anti-inflammatory drug versus placebo.

Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.

Conditions

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Frank Ruschitzka, Prof MD · University Hospital Zurich, Division of Cardiology

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427284 on ClinicalTrials.gov